Abstract
The recent discovery of IL-17-producing CD4(+) Th subset significantly revised the Th1/Th2 dichotomy model proposed by Mosmann and Coffman almost two decades ago. Th17 cells are involved in the pathogenesis of many human autoimmune diseases. Th17 cells, their developmental pathways and their effector functions, therefore, provide novel therapeutic targets.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use
-
Autoimmune Diseases / drug therapy*
-
Autoimmune Diseases / immunology
-
Clinical Trials as Topic
-
Cytokines / antagonists & inhibitors
-
Cytokines / immunology*
-
Humans
-
Interleukin-17 / antagonists & inhibitors
-
Interleukin-17 / genetics
-
Interleukin-17 / immunology*
-
Interleukin-17 / metabolism
-
Neoplasms / drug therapy*
-
Neoplasms / immunology
-
Nuclear Receptor Subfamily 1, Group F, Member 3
-
Oligonucleotides, Antisense / immunology
-
Oligonucleotides, Antisense / therapeutic use
-
Receptors, Aryl Hydrocarbon / immunology
-
Receptors, Aryl Hydrocarbon / metabolism
-
Receptors, Retinoic Acid / immunology
-
Receptors, Retinoic Acid / metabolism
-
Receptors, Thyroid Hormone / immunology
-
Receptors, Thyroid Hormone / metabolism
-
T-Lymphocytes, Helper-Inducer / immunology*
-
T-Lymphocytes, Helper-Inducer / metabolism
-
Transforming Growth Factor beta / antagonists & inhibitors
-
Transforming Growth Factor beta / immunology*
Substances
-
Antibodies, Monoclonal
-
Cytokines
-
Interleukin-17
-
Nuclear Receptor Subfamily 1, Group F, Member 3
-
Oligonucleotides, Antisense
-
RORC protein, human
-
Receptors, Aryl Hydrocarbon
-
Receptors, Retinoic Acid
-
Receptors, Thyroid Hormone
-
Transforming Growth Factor beta